PCM
STLN

Penserra Capital Management’s Starling Oncology STLN Stock Holding History

Penserra Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,121
Closed -$10K – 1211
2022
Q2 		$10K Sell
2,121
-929
-30% -$6.77K ﹤0.01% 1256
2022
Q1 		$21K Sell
3,050
-1,988
-39% -$13.4K ﹤0.01% 1248
2021
Q4 		$49K Buy
5,038
+1,083
+27% +$9.63K ﹤0.01% 1026
2021
Q3 		$39K Buy
+3,955
New +$39.3K ﹤0.01% 1118

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Penserra Capital Management's STLN Position: Q3 2022 in Review

Penserra Capital Management sold out of Starling Oncology (STLN) in Q3 2022, closing a stake of 2,121 shares — an estimated $10K sold.

Penserra Capital Management first reported a position in STLN in Q3 2021 and held it in 4 quarters. The position peaked at $49K in Q4 2021. 39 funds tracked by Wall St. Rank hold STLN as of Q3 2022.

  • Penserra Capital Management reported no remaining Starling Oncology position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 2,121 Starling Oncology shares in Q3 2022, an estimated $10K.
  • Penserra Capital Management first reported a position in Starling Oncology in Q3 2021 and held it in 4 quarters.
  • Penserra Capital Management's Starling Oncology position peaked at $49K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.